United Therapeutics Corporation $UTHR Stock Holdings Increased by Corient Private Wealth LLC

Corient Private Wealth LLC grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 13.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 19,248 shares of the biotechnology company’s stock after acquiring an additional 2,289 shares during the quarter. Corient Private Wealth LLC’s holdings in United Therapeutics were worth $9,379,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC raised its position in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the period. Finally, Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $317,617,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 1.0%

Shares of UTHR stock opened at $549.66 on Thursday. The company has a market capitalization of $23.33 billion, a price-to-earnings ratio of 20.29, a P/E/G ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The stock’s fifty day simple moving average is $562.63 and its 200-day simple moving average is $525.08.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $6.63 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.49 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,540,358.40. This represents a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 633,718 shares of company stock worth $358,492,749 over the last quarter. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on UTHR shares. HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada cut their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.